Phase II trial of induction immunotherapy with atezolizumab for patients with unresectable stage IIIA and IIIB NSCLC eligible for chemoradiotherapy with curative intent.

IRB/UVA Tracking #
20307
Contact
Maria Davenport
Contact Email
Contact Phone
+1 .434.4-29
Phase
II
Primary purpose
Treatment
Cancer PI
Richard Hall
Status
OPEN TO ACCRUAL